Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women

Lancet

Volumn 352, Issue 9122, 1998, Pages 93-97

  Veronesi, U ^a   Maisonneuve, P ^a   Costa, A ^a   Sacchini, V ^a   Maltoni, C ^b   Robertson, C ^a   Rotmensz, N ^a   Boyle, P ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b Fondazione Europea B Rammazini   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; TAMOXIFEN; TRIACYLGLYCEROL;

ARTICLE; BREAST CANCER; CANCER INCIDENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EMBOLISM; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPERTRIGLYCERIDEMIA; HYSTERECTOMY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOPHLEBITIS; VASCULAR DISEASE; VEIN THROMBOSIS;

EID: 0032508293     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)85011-3     Document Type: Article

References (20)

1. Jordan VC, Naylor KE, Dix CJ, Prestwich G. Anti-oestrogen action in experimental breast cancer. Recent Results Cancer Res 1980; 71: 30-44.
2. Colletta AA, Benson JR, Baum M. Alternative mechanisms of action of anti-oestrogens. Breast Cancer Res Treat 1994; 31: 5-9.
3. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-67.
4. Nolvadex Adjuvant Trial Organisation (NATO), Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 1988; 57: 608-11.
5. Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet 1985; ii: 282.
6. Bonadonna G, Valagussa P, Brambilla C, Moliterri A, Zambetti M, Ferrari L. Adjuvant and neoadjuvant treatment of breast cancers with chemotherapy and/or endocrine therapy. Semin Oncol 1991; 18: 515-24.
7. Fisher B, Redmond C. New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventing agent. J Natl Cancer Inst 1991; 83: 1278-80.
8. Creaseman WT. Endometrial cancer: incidence, prognostic factors, diagnosis and treatment. Semin Oncol 1997; 24: s1-40-50.
9. MacMahon B. Overview of studies on endometrial cancer and other types of cancer in humans: perspectives of an epidemiologist. Semin Oncol 1997; 24: s1-122-39.
10. Forbes JF. The control of breast cancer: the role of tamoxifen. Semin Oncol 1997; 24: s1-5-19.
11. Veronesi U, Costa A, Boyle P, et al. Prevention of breast cancer with tamoxifen: the Italian study in hysterectomized women. Breast 1995; 4: 267-72.
12. Boyle P. The epidemiology of breast cancer In: Veronesi U, ed. Bailliere's Clin Oncol 1988; 2: 1-58.
13. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047-59.
14. Eaker ED, Chesboro JH, Sacks FM, Wenger NK, Whisnant JP, Winston M. Cardiovascular disease in women. Circulation 1993; 88: 1999-2007.
15. Glueck CJ, Lang J, Harner T, Tracy T. Severe hypertriglyceridaemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridaemic women. J Lab Clin Med 1994; 123: 59-64.
16. Brun LD, Gagne C, Rousseau C, Moorjani S, Lupien PJ. Severe lipaemia induced by tamosifen. Cancer 1986; 57: 2123-26.
17. Kanel KT, Wolmark N, Thompson PD. Delayed severe hypertriglyceridaemia from tamoxifen. N Engl J Med 1997; 337: 281.
18. Thangaraju M, Kumar K, Gandhirajan R, Sachdanandam P. Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer. Cancer 1994; 73: 659-63.
19. Love RR, Newcomb PA, Wiebe DA, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 1990; 82: 1327-32.
20. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996; 88: 1529-42.